Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity.

ABSTRACT:

Background

Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion.

Objective

Our study highlights the impact of Irinotecan on gut microbiota composition and the role of probiotics in limiting Irinotecan-associated diarrhea and suppressing gut bacterial β-glucuronidase enzymes.

Material and methods

To investigate the effect of Irinotecan on the gut microbiota composition, we applied 16S rRNA gene sequencing in three groups of stool samples from healthy individuals, colon cancer, and Irinotecan treated patients (n = 5/group). Furthermore, three Lactobacillus spp.; Lactiplantibacillus plantar

SUBMITTER: Mahdy MS 

PROVIDER: S-EPMC9979425 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature